| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 216.83 | 19.5% |
| Total Income | 216.83 | 19.5% |
| Expenditure | 184.19 | 7.6% |
| PBT | 24.33 | 133.9% |
| Net Profit | 24.33 | 133.9% |
| OPM | 15.05% | 24.97pp |
| NPM | 11.22% | 50.79pp |
| EPS | 0.09 | 101.1% |
Caris Life Sciences Reports Q3 2025 Revenue Up 113.4% Y/Y
04 May 2026 · 4 May, 7:57 am
Summary
Caris Life Sciences reported a record quarter with revenue of $216.8 million, up 113.4% year-over-year, driven by strong performance in molecular profiling services. The company achieved net income of $24.3 million and positive adjusted EBITDA of $51.2 million. Caris raised its full-year 2025 revenue guidance to $720 to $730 million, projecting a growth of 75% to 77%. The increase in revenue was primarily driven by a 121.3% growth in molecular profiling services revenue.
Key Highlights
- 1
Total revenue for Q3 2025 was $216.8 million, representing a 113.4% increase over the prior year period.
- 2
The company completed 50,763 clinical therapy selection cases, an 18.2% increase year-over-year.
- 3
Gross margin improved to 68.0%, a 2,432 bps improvement compared to the corresponding prior year period.
- 4
Caris Life Sciences achieved net income of $24.3 million in Q3 2025.
- 5
Adjusted EBITDA was reported as $51.2 million for the quarter.
- 6
The company reported positive net cash flow from operating activities of $62.4 million and positive free cash flow of $55.3 million.
- 7
Full-year 2025 revenue guidance was raised to a range of $720 to $730 million, representing 75% to 77% year-over-year growth.
Management Comments
David D. Halbert
We delivered another record quarter for revenue and clinical volume, achieving positive net income and demonstrating the operating strength of our comprehensive, patient-first approach. These results reflect the core strength of our business and our continued progress toward delivering the next generation of personalized solutions through our exciting pipeline in MRD and early detection.
Informational and educational content only. Not investment advice.